Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IN8BIO, INC. (INAB)

IN8bio Signs $ Sales Agreement With JonesTrading for At-the-Market Share Sales

Neutral Impact 3 of 5 financing Written later

IN8bio entered a Capital on Demand sales agreement with JonesTrading dated June 1, 2026, allowing it to sell new common stock from time to time at its discretion under an at-the-market program. It also terminated its prior Cantor Fitzgerald sales agreement, effective May 29, 2026, with no termination penalties, and the new program means the company can issue additional shares that could dilute existing holders.

Key points

  • New sales agreement with JonesTrading Institutional Services LLC dated June 1, 2026
  • JonesTrading commission is 3.0% of gross sales proceeds
  • Cantor Fitzgerald sales agreement from November 10, 2022 terminated effective May 29, 2026
  • Shares to be sold under Form S-3 registration statement (File No. 333-291393)

The filing

CompanyIN8BIO, INC. (INAB)
Form8-K, current report
Filed with the SECJun 1, 2026, 6:56 AM ET
Accession number0001193125-26-249684

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.